Bio-Techne Corp (TECH) Social Stream
BIO-TECHNE Corp (TECH) Price Targets From Analysts
Use the tables below to see what analysts covering BIO-TECHNE Corp think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-02 | 9 | $600 | $400 | $510.625 | $433.04 | 17.92% |
| 2021-12-01 | 9 | $600 | $400 | $511.875 | $433.04 | 18.21% |
| 2022-02-01 | 9 | $600 | $400 | $506.25 | $433.04 | 16.91% |
| 2022-03-01 | 6 | $600 | $540 | $565 | $433.04 | 30.47% |
The Trend in the Analyst Price Target
Over the past 44 weeks, TECH's average price target has gone up $142.22.
Over the past 47 weeks, TECH's average upside potential has been 10.84%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-06-13 | 8 | 500 | 410 | 453.890 | 443.94 | 2.24% |
| 2021-06-26 | 8 | 500 | 410 | 453.890 | 436.54 | 3.97% |
| 2021-09-04 | 8 | 590 | 490 | 540.670 | 513.09 | 5.38% |
| 2021-11-02 | 9 | 600 | 400 | 510.625 | 503.33 | 1.45% |
| 2022-02-01 | 7 | 600 | 410 | 542.500 | 401.57 | 35.09% |
TECH Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 6 | 0 | 0 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
TECH's average broker recommendation rating improved by 0.73 over the prior 151 days.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- BIO-TECHNE Corp's average analyst price target is greater than 687.53% of all US stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, BIO-TECHNE Corp's upside potential (average analyst target price relative to current price) is greater than 76.29% of them.
- TECH has a higher number of analysts covering the stock than 159.9% of stocks in the large market cap category.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, BIO-TECHNE Corp's variance in analysts' estimates is lower than -72.42% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to BIO-TECHNE Corp are SGEN, RGEN, and QGEN.
What is the outlook for TECH? Use POWR Ratings for clearer insight into price direction.